Clear market notes built around the JSE, the rand, and what matters locally.

2026-07-31 17:30 • The Motley Fool Positive Axe Cap view: Selective

Eli Lilly has significantly outperformed Novo Nordisk in the booming GLP-1 obesity drug market, with Lilly commanding 60% market share compared to Novo's smaller portion of the combined 87% duopoly. While the obesity drug market is projected to grow from $66 billion in 2025 to $120 billion by 2030, Lilly's stock has surged 58% over 52 weeks, whereas Novo has plummeted 62% since July 2024. However, Novo's recent launch of a pill-form obesity drug could shift the competitive landscape.

Axe note: Eli Lilly’s dominant market share drives stock gains, while Novo Nordisk's new pill faces an uphill battle.

2026-07-31 17:11 • The Motley Fool Mixed Axe Cap view: Selective

Amazon surged 14.9% after reporting strong Q2 earnings with AWS growing 37% year-over-year, adding 208 points to the Dow. Apple fell 9.4% despite solid Q3 results due to muted guidance citing chip supply constraints, subtracting 188 points from the index. The market remains driven by mega-cap tech stocks with strong AI cloud businesses, while most other stocks declined.

Axe note: Amazon’s cloud strength drives markets while Apple’s chip caution warns of supply chain limits.

2026-07-31 17:07 • The Motley Fool Positive Axe Cap view: Selective

Bernstein raised its Robinhood price target from $130 to $160, citing a major shift in the company's revenue streams. Prediction-market trading has become Robinhood's largest revenue source at $156 million in Q2 2026, surpassing crypto trading ($100 million) and equity trading ($129 million). The firm projects prediction-market revenue will grow at a 64% compound annual rate, driven by retail investors seeking ways to profit in down markets.

Axe note: Robinhood's rising prediction-market revenue catches Bernstein’s attention with strong growth potential.